$4.2B deal: GSK and Merck KGaA to develop cancer immunotherapy

GlaxoSmithKline is teaming up with Merck KGaA of Germany in a multibillion-deal to jointly develop an experimental immunotherapy treatment for multiple difficult-to-treat cancers.

Under the terms of the agreement, GSK (NYSE: GSK) will make an $342.8 million upfront payment to Merck KGaA, which will be also be eligible for up to $571 million in potential development milestone payments and $3.3 billion approval and commercial milestone payments.

The deal total potential value is $4.2 billion.


Previous Lucina Health names new CFO
Next Colorado renters could see fees limited or even returned if new bill becomes law

No Comment

Leave a reply

Your email address will not be published. Required fields are marked *